Περίληψη:
The use of high-efficacy disease-modifying therapies (DMTs) early in the course of multiple sclerosis (MS) has been shown to improve clinical outcomes and is becoming an increasingly popular treatment strategy. As a result, monoclonal antibodies, including natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab, are frequently used for the treatment of MS in women of childbearing age. To date, only limited evidence is available on the use of these DMTs in pregnancy. We aim to provide an updated overview of the mechanisms of action, risks of exposure and treatment withdrawal, and pre-conception counseling and management during pregnancy and post-partum of monoclonal antibodies in women with MS. Discussing treatment options and family planning with women of childbearing age is essential before commencing a DMT in order to make the most suitable choice for each individual patient. © 2023 by the authors.
Λέξεις-κλειδιά:
alemtuzumab; monoclonal antibody; natalizumab; ocrelizumab; ofatumumab; ublituximab, breast feeding; clinical outcome; drug efficacy; evidence based practice; family planning; human; multiple sclerosis; pregnancy; Review
